Jefferies keeps Endo at buy

Endo Pharmaceuticals Holdings, Inc. was maintained at a buy rating by Jefferies & Co., Inc. analyst David Windley as Lidoderm sales trend toward the high end of guidance despite weaker-than-expected first-quarter 2006 sales. Jefferies is keeping its 2006 and 2007 earnings-per-share estimates at $1.75 and $1.92, forecasting 2006 revenue of $880 million, the high end of guidance. Shares of the Chadds Ford, Pa., pharmaceutical company were down 77 cents, or 2.39%, at $31.42 on volume of 1,350,802 shares versus the three-month running average of 1,540,030 shares. (Nasdaq: ENDP)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.